ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
Rhea-AI Summary
ImmuCell (Nasdaq: ICCC) announced two board appointments and a governance restructure effective April 15, 2026. Dr. Gilles Guillemette and Dr. Anthony DiMarco join the board; the company will move to a seven-person board with six independent directors and create a Strategy and Technology Committee.
The new committee will be chaired by Dr. Guillemette and includes members focused on manufacturing yield, capacity expansion, and innovation-driven growth of the First Defense® product line.
Positive
- Board reduced to a 7-person structure with 6 independent directors
- Creation of a Strategy and Technology Committee to guide innovation
- Appointment of Dr. Gilles Guillemette to chair the new committee
- Appointment of Dr. Anthony DiMarco with manufacturing and R&D expertise
Negative
- Three directors will retire effective April 15, 2026, reducing board continuity
- Board turnover could temporarily disrupt governance during committee formation
News Market Reaction – ICCC
In the Apr 14 session, ICCC gained 8.72%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.1x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Prelim Q1 sales | Positive | +12.7% | Strong preliminary Q1 2026 product sales growth versus prior year. |
| Mar 18 | Board appointment | Positive | +1.8% | Addition of experienced animal health executive Kathy Turner to board. |
| Mar 04 | Full-year results | Positive | -1.7% | Unaudited 2025 results with higher sales, margins and narrower loss. |
| Feb 18 | Earnings date notice | Neutral | +3.9% | Announcement of timing for Q4 and full-year 2025 results and call. |
| Jan 08 | Prelim Q4/FY sales | Negative | -1.1% | Preliminary 2025 sales with Re-Tain impairment and inventory write-downs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ICCC has generally reacted positively to strong sales updates and strategic news, with only one recent divergence on full-year earnings.
Over the past six months, ImmuCell has reported several operational and strategic milestones. Preliminary Q1 2026 sales of $10.4M on Apr 08 drove a 12.7% gain, following earlier preliminary 2025 sales on Jan 08 that included write-downs and saw a modest -1.14% move. Unaudited 2025 results released on Mar 04 showed $27.6M in sales and improved margins but were followed by a -1.7% reaction. Board and earnings-date announcements in February and March produced smaller positive moves, framing today’s board refresh within an ongoing execution and governance narrative.
Key Terms
hyperimmune colostrum medical
colostrum-derived medical
antibodies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors.
Dr. Guillemette has more than 30 years of executive experience in animal health therapeutics. He has held executive positions at Elanco, Bayer, Henry Schein, Chewy, and Trupanion, where he had significant P&L responsibilities, led strategy, business development and finance functions, and managed regulated therapeutic operations. Dr. Guillemette is currently an Operating Partner at Archimed and earned his Doctor of Veterinary Medicine in Nantes, France. He will Chair the new Strategy and Technology Committee and serve on the Audit Committee.
Dr. DiMarco brings four decades of scientific leadership in human and animal health biologics companies. For 21 years, he was Vice President of R&D and Global Manufacturing at IDEXX where he developed new products and implemented productivity improvements. Previously, Dr. DiMarco spent 10 years in scientific roles at Abbott Laboratories. Dr. DiMarco serves as Chair of Educate Maine and received his Ph.D. in Microbiology from the University of Illinois. He will serve on the Compensation, Nominations, and Strategy & Technology Committees.
Dr. DiMarco said, “My first introduction was in helping ImmuCell develop a manufacturing yield improvement plan and I look forward to working with the team to consider opportunities to further develop hyperimmune colostrum technology and expand the First Defense® line.” Mr. Guillemette added, “This is an exciting time to join the ImmuCell Board as the company develops and executes new innovation strategies to accelerate the growth of First Defense®.”
“Dr. Guillemette strengthens our board with expertise in animal health strategy and M&A, complemented by a veterinary background that will help us develop an innovation strategy based on clinical relevance,” commented Olivier te Boekhorst, President and Chief Executive Officer of ImmuCell. “Dr. DiMarco brings experience improving biological manufacturing processes and a track record of developing successful new animal health products. Joined by Gloria Basse and Kathy Turner, they will serve on our new Strategy and Technology Committee that will support management with strategic and technical expertise as we pursue opportunities to improve our yield, expand our capacity, and generate innovation-driven growth of First Defense®. We are also pleased to advance our corporate governance by moving to an independent board.”
The Company is moving to a 7-person Board of Directors with six Independent Directors and the CEO and gratefully acknowledges the many valuable contributions and dedicated service of Bryan Gathagan and non-independent members Michael Brigham and Bobbi Brockmann, who will retire from the Board effective April 15, 2026, and Timothy Fiori who will retire from the Board after the 2026 Annual Meeting. Ms. Brockmann and Mr. Fiori will continue their executive roles at the Company.
Effective April 15, 2026, the independent members of the Board of Directors of ImmuCell will be Dr. David Tomsche DVM (Chair), Ms. Gloria Basse, Dr. Anthony DiMarco Ph.D., Dr. Gilles Guillemette DVM, Ms. Kathy Turner, and Mr. Paul Wainman.
About ImmuCell
ImmuCell Corporation (Nasdaq: ICCC) is an animal health biologics company serving the dairy and beef industries with practical, science-based solutions that improve the survivability, health, and long-term performance of dairy and beef calves. The Company’s primary product line, First Defense®, provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours, one of the most prevalent and deadly diseases in neonatal calves worldwide. The Annual Meeting of Stockholders of ImmuCell Corporation will be held remotely via a live audio webcast as well as by telephone conference call on Thursday, June 11, 2026 at 9:30 AM ET. Press releases and other information about the Company, including an updated Investor Presentation that provides an overview of the Company’s business, are available at http://www.immucell.com/investors.
| Contacts: | Olivier te Boekhorst, President and CEO | |
| Timothy C. Fiori, Chief Financial Officer | ||
| ImmuCell Corporation | ||
| investor.relations@immucell.com | ||
| Joe Diaz, Robert Blum and Joe Dorame | ||
| Lytham Partners, LLC | ||
| iccc@lythampartners.com |
